Shanghai, China, October 30, 2024-WuXi XDC Cayman Inc. (“WuXi XDC” or the “Company”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (“CRDMO”) focused on antibody drug conjugates (ADC) and other bioconjugates, has been awarded a “Low Risk” rating in the 2024 ESG (Environmental, Social, and Governance) corporate risk assessment by Morningstar Sustainalytics. This recognition places WuXi XDC among the top 10% of companies evaluated globally, reaffirming its leadership position in the CRDMO field. This rating reflects our excellent performance in corporate governance, human rights, labor practices, environmental stewardship, community engagement, and sustainable development management.
Morningstar Sustainalytics is an authoritative company providing ESG data, research, and ratings covering a wide range of topics, helping global investors formulate and implement responsible investment strategies. The risk rating system of Morningstar Sustainalytics consists of three main parts: corporate governance, ESG issues, and company-specific issues, covering various comprehensive indicators in the environmental (E), social (S), and governance (G) dimensions. This year, Morningstar Sustainalytics rated over 16,000 companies for ESG risks, and WuXi XDC received high recognition.
Dr. Jimmy Li, CEO of WuXi XDC, stated, “Receiving this rating from Morningstar Sustainalytics is a testament to our continuous efforts to enhance our ESG capabilities. ESG principles are integral to our corporate ethos and development strategy, and we are dedicated to advancing ESG excellence, creating long-term societal value, and fulfilling our commitment to sustainable growth for both the company and the wider society. Moving forward，we will continue to strengthen our ESG management, implement innovative governance practices, and champion sustainable development initiatives. Pursuing ESG excellence remains our focus, and we are committed to making even greater strides and achieving more impactful milestones.”
About Morningstar Sustainalytics
Morningstar Sustainalytics provides high-quality, analytical environmental, social and governance (ESG) research, ratings and data to institutional investors and companies. For more than 30 years, the firm has focused on delivering innovative solutions that have enabled the world’s leading institutional investors to identify, understand, and manage ESG-driven risks and opportunities. With Sustainalytics now a part of Morningstar, the firm is accelerating efforts to bring meaningful ESG insights to investors of all types across different asset classes at the company and fund level.
About WuXi XDC
WuXi XDC Cayman Inc. (“WuXi XDC” or the “Company”, stock code: 2268.HK) is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com.
WuXi XDC Contacts
ESG：ESG_WuXi_XDC@wuxibiologics.com
Investor：wuxixdc.ir@wuxibiologics.com
Media：wuxixdc_pr@wuxibiologics.com
BD：wuxixdc_info@wuxibiologics.com
About Us
Services & Solutions
Investor Relations
News & Resources
